Kidney Dialysis Survival Rates: AAV Doesn’t Impact Outcome

The news coming out of the December 2025 Kidney International Reports study is a sobering, yet potentially hopeful, one for the nearly 400 patients examined. Researchers found that while baseline dialysis significantly worsens outcomes for individuals with antineutrophil cytoplasmic autoantibody (AAV)-associated vasculitis and kidney involvement, the overall one-year survival rate – factoring in death or end-stage kidney disease – isn’t dramatically different between those starting dialysis and those who aren’t. This is particularly relevant here in Chicago, a city with a large and diverse population, and a significant number of patients receiving treatment at institutions like Northwestern Memorial Hospital and the University of Chicago Medical Center.

Understanding AAV and its Impact on Kidney Health

AAV is a group of autoimmune diseases characterized by inflammation of slight blood vessels. When it affects the kidneys, it can lead to rapidly progressive glomerulonephritis, a condition that damages the filtering units of the kidneys. This damage can quickly lead to kidney failure, necessitating dialysis. The study highlights the challenge of predicting which patients will require dialysis at the time of diagnosis and, crucially, what their long-term prognosis will be. The updated ANCA Kidney Risk Score (AKRiS), building on the earlier ANCA Renal Risk Score, aims to improve this prognostication, but as the research shows, there’s still considerable uncertainty.

The study, a retrospective multicenter analysis, included 394 patients with biopsy-proven renal AAV. A substantial 26.6% – 105 patients – were already on dialysis when they entered the study. The results were stark: 57.1% of those on baseline dialysis reached the composite endpoint of death or end-stage kidney disease, compared to just 10% of those who weren’t. However, the researchers as well noted that age and sex weren’t significant factors in the outcome. What *was* significant was the presence of myeloperoxidase (MPO)-ANCA antibodies and a high baseline histologic renal risk score. This suggests that the type of antibody involved and the initial severity of kidney damage are key predictors of how a patient will fare.

Plasma Exchange and the Ongoing Debate

The role of plasma exchange (PLEX) in treating AAV-associated kidney disease remains a contentious issue. The study acknowledges that the benefit of PLEX has been questioned, and the ideal patient population for this treatment isn’t clearly defined. PLEX works by removing harmful antibodies from the blood, but its effectiveness appears to vary depending on the individual patient and the specific characteristics of their disease. The researchers in this study didn’t specifically focus on PLEX, but the broader debate underscores the demand for more refined strategies for managing AAV and protecting kidney function. The Ann & Robert H. Lurie Children’s Hospital of Chicago, for example, is actively involved in research exploring novel immunotherapies for autoimmune diseases, potentially offering future alternatives to traditional treatments like PLEX.

The Chicago Context: Access to Care and Specialized Expertise

Chicago, with its concentration of world-class medical facilities, is relatively well-positioned to provide specialized care for patients with AAV. However, access to these resources isn’t always equitable. Patients from underserved communities on the South and West Sides may face barriers to timely diagnosis and treatment. The complexity of AAV requires a multidisciplinary approach involving nephrologists, rheumatologists, and pathologists – expertise that isn’t uniformly available across all healthcare settings. The Illinois Kidney Foundation plays a vital role in supporting patients with kidney disease throughout the state, offering financial assistance and educational resources, but more needs to be done to address disparities in care.

Navigating AAV and Kidney Disease: A Local Resource Guide

Given my background in healthcare administration and a focus on patient advocacy, if this trend impacts you or a loved one in the Chicago area, here are three types of local professionals you’ll want to consider consulting:

Specialized Nephrologists:

Look for a nephrologist with specific experience in treating autoimmune kidney diseases like AAV. They should be board-certified in nephrology and ideally have a fellowship in autoimmune kidney disease. Ask about their experience with PLEX and other advanced therapies. A strong candidate will be affiliated with a major Chicago hospital system.

Rheumatologists with Vasculitis Expertise:

A rheumatologist is crucial for managing the underlying autoimmune process driving AAV. Seek a rheumatologist who specializes in vasculitis and has a deep understanding of the different types of AAV and their treatment options. They should be comfortable collaborating with a nephrologist to provide coordinated care.

Medical Social Workers specializing in Chronic Illness:

Living with AAV and potential kidney failure can be incredibly challenging, both physically and emotionally. A medical social worker can provide support with navigating the healthcare system, accessing financial assistance, and coping with the psychological impact of the disease. Look for a social worker with experience working with patients with chronic illnesses and a strong understanding of local resources.

Ready to find trusted professionals? Browse our complete directory of top-rated healthcare experts in the Chicago area today.